Four IV therapies are being sold for ME/CFS — an evidence review finds no convincing trial data behind any of them
Edited by Samael A. Tejada, Founder & Editor-in-Chief
·Tip: press play, then lock your phone or switch apps — the article keeps reading.
Four IV therapies marketed for ME/CFS — EBOO ozonation, IV methylene blue, IV procaine and IV stem-cell infusions — have no convincing controlled-trial evidence behind them, an expert review found (November 11, 2026). The mitochondrial rationale for some is laboratory-only, and at least one carries a potentially fatal drug-interaction warning.
When an illness has no approved treatment and a plausible energy story — ME/CFS involves impaired cellular energy production — the market does not wait for trials. This review reads the fine print on four therapies already being sold.
What did the review examine?
Four IV therapies marketed to ME/CFS patients: EBOO (extracorporeal blood oxygenation and ozonation), IV methylene blue, IV procaine, and infusions of mesenchymal stromal cells (MSCs). For each, the review asked a simple question: is there controlled-trial evidence in ME/CFS? The answer, for all four, was no.
Where does the marketing outrun the data?
EBOO's promotion cites a 200-patient study reporting 77.5% improvement on a fatigue scale at about 30 days — but that study was uncontrolled, and it tested a different procedure (oxygen-ozone autohemotherapy). IV methylene blue's mitochondria rationale is real but laboratory-only: it can shuttle electrons in mitochondria in cell and animal models, with no ME/CFS patient trials. IV procaine had the weakest disease-specific evidence of the four. And commercial 'stem cell' infusions are not an FDA-approved product — the one approved MSC therapy, Ryoncil (December 2024), is approved only for a specific paediatric transplant complication. By contrast, the review notes one oral combination with an actual randomised trial behind it — CoQ10 200 mg/day plus NADH 20 mg/day over 12 weeks in 207 patients, which significantly reduced cognitive fatigue — while stressing it needs replication.
What are the risks patients may not hear about?
Methylene blue carries an FDA boxed warning: combined with serotonergic drugs such as SSRIs, SNRIs, tramadol or dextromethorphan, it can trigger potentially fatal serotonin syndrome — a serious concern in a patient group often prescribed those medicines. It is also contraindicated in G6PD deficiency because it can cause haemolysis. Unapproved cell infusions add the general risks of unregulated biologics. None of this means every idea here is worthless — it means the evidence has not been done, and the marketing should not pretend otherwise.
Frequently asked questions
Why do IV clinics market to ME/CFS patients?
ME/CFS has no FDA-approved treatment and involves impaired energy production, which makes mitochondrial-sounding therapies easy to market — and makes rigorous evidence checks especially important.
Is methylene blue dangerous?
It has legitimate medical uses, but IV use with common antidepressants (SSRIs/SNRIs and similar) can cause potentially fatal serotonin syndrome — the subject of an FDA boxed warning — and it is contraindicated in G6PD deficiency.
Is any therapy better supported for ME/CFS fatigue?
The review points to an oral CoQ10 plus NADH combination tested in a 12-week randomised trial of 207 patients as a stronger — still preliminary — signal. It is not an IV therapy and not an approved treatment.
Where the evidence stands
- Established: ME/CFS has no FDA-approved treatment and involves impaired cellular energy production. Methylene blue's serotonin-syndrome interaction carries an FDA boxed warning.
- Contested: Whether laboratory mitochondrial effects of methylene blue or ozone-based procedures translate into patient benefit — plausible mechanisms, no controlled ME/CFS data.
- Absent: Convincing controlled-trial evidence for EBOO, IV methylene blue, IV procaine or IV MSC infusions in ME/CFS.
Join the discussion
To get the conversation started: What questions does this story raise for you? Share them below — every comment is reviewed by our moderators before it appears.
Community discussion only — not medical advice. Every comment is reviewed by our moderators before it appears. Sign in with Google or a free Hyvor account to join in.